Valerii I. Podzolkov

Valerii I. Podzolkov

Auto-generated profile, based on publicly available information

Valerii I. Podzolkov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2020 in Kidney and Blood Pressure Research
Verified
Journal Article
Open access
PDF file
VPValery I. Podzolkov
Valery I. Podzolkov
ABAnna E. Bragina
Anna E. Bragina
NDNatalya Druzhinina
Natalya Druzhinina
LVLubov V. Vasil’eva
Lubov V. Vasil’eva
KOKonstantin K. Osadchiy
Konstantin K. Osadchiy
EKEvgeny I. Khvalin
Evgeny I. Khvalin
Introduction/Objective: Tobacco smoking is a well-known risk factor for cardiovascular and renal diseases. In recent years, alternative types of smoking, including vaping, have been becoming popular. The contribution of vape to vascular and renal injury is not known. We studied the relation between smoking of traditional/electronic cigarettes and arterial stiffness and albuminuria, which is also a vascular dysfunction marker. Methods: We examined 270 young volunteers without significant clinical cardiovascular diseases (mean age: 21.2 ± 2.3 years). Twenty-seven percent of the subjects in the study group were smokers; 69.9% of them smoked traditional cigarettes and 30.1% smoked electronic cigarettes. The urine albumin level was assessed by a dipstick test, and the augmentation index was determined by photoplethysmography. A linear correlation test and multiple regression analysis were applied. Results: The study groups did not differ in basic characteristics. The smokers demonstrated generally higher blood pressure levels and were overweight. Most of the smokers were male. In the groups of smokers, albuminuria was more frequent, especially among vapers (94 vs. 79% in tobacco smokers and 29% in nonsmokers). AU values (median [quartile 25; quartile 75]) were significantly higher in vapers (160 mg/L [150; 207.5]) vs. tobacco smokers (115 mg/L [60; 200]) and vs. nonsmokers (20 mg/L [10; 50]) (р < 0.05). Photoplethysmographic results showed relevant higher augmentation indices among tobacco smokers (–4, [–6.6; –1.9]) and vapers (–5.05 [–13.4; –3.3]) compared to nonsmokers (–16.2 [–23.9; –7]) (р < 0.05). Results of multiple regression analysis demonstrate that smoking of both traditional and electronic cigarettes is related to an increase in the albuminuria level and the augmentation index. Conclusions: Smoking of both traditional and electronic cigarettes is related to albuminuria and an increase in the augmentation index, which is a noninvasive marker for arterial stiffness.

25 December 2024 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
ICI. E. Chazova
I. E. Chazova
NCN. M. Chikhladze
N. M. Chikhladze
NBN. V. Blinova
N. V. Blinova
AAA. V. Aksenova
A. V. Aksenova
TAT. A. Alekseeva
T. A. Alekseeva
GSG. V. Shchelkova
G. V. Shchelkova
The сlinical guidelines present the main approaches to the management of patients with arterial hypertension (aH) using the principles of evidence-based medicine. The guidelines include sections containing expanded and updated information on the main aspects of diagnosis, treatment, prevention methods and follow-up patients with hypertension, taking into account the phenotypes of disease and various clinical situations, as well as secondary forms of hypertension of various origins.

15 March 2021 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
OOOlga D. Ostroumova
Olga D. Ostroumova
VPVladimir Parfenov
Vladimir Parfenov
TOTatiana M. Ostroumova
Tatiana M. Ostroumova
NYNikolay N. Yakhno
Nikolay N. Yakhno
ICIrina E. Chazova
Irina E. Chazova
ШВШих Евгения Валерьевна
Ших Евгения Валерьевна
Arterial hypertension (AH) is the major modifiable risk factor for cognitive impairment (CI), including dementia, CI in cerebrovascular and neurodegenerative diseases, including Alzheimers disease. By 2050, the number of people with dementia will approximately 3 times increase due to the aging population and limited opportunities for drug prevention and treatment of severe CI. In connection with the above, it seems necessary to create an expert consensus, which would summarize the evidence-based medicine data available to date on the effect of antihypertensive therapy (AHT) on cognitive function (CF). In the expert consensus, the data of prospective randomized clinical trials, observational and population studies, meta-analyzes on the effect of AHT on the risk of dementia and CI progression, including certain CF, were summarized and analyzed. The consensus considers the effect of antihypertensive drugs (AHD) on various cognitive domains. Literature data give evidence that AHT reduces the risk for dementia, including vascular dementia, reduces the risk of for dementia in Alzheimers disease, as well as reduces the risk and can prevent the progression of non-dementia CI. The effect of AHT on various CF has been little studied. Most meta-analyzes did not reveal the benefits of any class of AHD; however, one study demonstrated the advantage of angiotensin receptor blockers, while another study diuretics. The consensus emphasizes that, given the high incidence of AH in the general population, AHT may be one of the most effective ways to prevent CI or delay CI progression. The effect of different classes of AHD on CF requires further study. It is necessary to conduct a larger number of well-designed randomized clinical trials that would assess the state of executive functions in patients with AH.

16 November 2022 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
ICI. E. Chazova
I. E. Chazova
YZYu. V. Zhernakova
Yu. V. Zhernakova
OKO. A. Kislyak
O. A. Kislyak
VPV. I. Podzolkov
V. I. Podzolkov
EOE. V. Oshchepkova
E. V. Oshchepkova
NBN. V. Blinova
N. V. Blinova
After 3 years since the release of the first consensus on the management of patients with hyperuricemia and high cardiovascular risk. During this time, new data appeared that confirm the importance of uric acid control as a risk factor for cardiovascular complications and allow optimizing the algorithm for managing such patients. Studies since the first consensus emerged have identified new hyperuricemia thresholds for cardiovascular risk. The present consensus regulates the prescription of urate-lowering therapy depending on the severity of the detected hyperuricemia. However, although a large body of data demonstrates a positive effect of urate-lowering therapy on the cardiovascular prognosis, there is a need for additional evidence to support the treatment of asymptomatic hyperuricemia.

26 May 2021 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
ICI. E. Chazova
I. E. Chazova
MSMarina Shestakova
Marina Shestakova
YZYu. V. Zhernakova
Yu. V. Zhernakova
NBN. V. Blinova
N. V. Blinova
TMT. N. Markova
T. N. Markova
ANA. R. Narzullaeva
A. R. Narzullaeva
ЕВРАЗИЙСКИЕ РЕКОМЕНДАЦИИ ПО ПРОФИЛАКТИКЕ И ЛЕЧЕНИЮ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ У БОЛЬНЫХ С ДИАБЕТОМ И ПРЕДИАБЕТОМ (2021)

7 May 2021 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
VPV. I. Podzolkov
V. I. Podzolkov
ABAnna E. Bragina
Anna E. Bragina
ATA. I. Tarzimanova
A. I. Tarzimanova
LVL. V. Vasil'EVa
L. V. Vasil'EVa
Elena BatrakovaElena Batrakova
Elena Batrakova
MKM. M. Khachuroeva
M. M. Khachuroeva
The coronavirus pandemic showed not only an increase in levels of excess morbidity and mortality in the acute phase, but also persisting symptoms 4 weeks after the onset of the disease. A review of international studies on the prevalence and diversity of the manifestations of postcoid syndrome is presented. The data on such a manifestation of post-COVID syndrome as postural orthostatic tachycardia syndrome (POTS) are accumulating. Pathogenetic mechanisms, modern diagnostic criteria and research data on the prevalence of this syndrome are presented in the article. The Canadian Cardiovascular Society has proposed medications as a treatment for POTS, including the sinus node If channel inhibitor ivabradine. Data from several studies showing the effectiveness of this drug for POTS, including after suffering COVID-19, are presented in the article. Clinical data on the prevalence of tachycardia among patients admitted to the Sechenov University hospital are presented. About 18% of patients with hypertension and 21% of patients with normal blood pressure had a high heart rate. A clinical example of the use of ivabradine in a patient after a coronavirus infection is presented. Drug interactions and individual tolerance of ivabradine in patients after coronavirus infection are being discussed. The authors put forward the hypothesis about the further prospect of using ivabradine in the treatment of clinical manifestations of postcoid syndrome on the basis of literature data and their own experience.